Dexmedetomidine in IVRA | NCT05123170 | Trialant

Dexmedetomidine in IVRA | NCT05123170 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Group I	Active Comparator	Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) alone diluted with normal saline 0.9% to make the final volume 30 ml	Drug: Lidocaine IV
Group II	Active Comparator	Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.25 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml.	Drug: Dexmedetomidine Injectable Solution [Dexdomitor] Drug: Lidocaine IV
Group III	Active Comparator	Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.5 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml	Drug: Dexmedetomidine Injectable Solution [Dexdomitor] Drug: Lidocaine IV

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Dexmedetomidine Injectable Solution [Dexdomitor]	Drug	two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
hollmen scale	change from base line for the scale (scale from 1 to 4)	2 hours
modified bromage scale	change from baseline for the scale (scale from 0 to 4 )	2 hours

Contacts/Locations Module

Intervention Browse Module